Idioma:

Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment

Nishida, Kosuke ; Morioka, Ichiro ; Nakamachi, Yuji ; Kobayashi, Yoko ; Imanishi, Takamitsu ; Kawano, Seiji ; Iwatani, Sota ; Koda, Tsubasa ; Deguchi, Masashi ; Tanimura, Kenji ; Yamashita, Daisuke ; Nibu, Ken-ichi ; Funakoshi, Toru ; Ohashi, Masanobu ; Inoue, Naoki ; Iijima, Kazumoto ; Yamada, Hideto

Brain & development (Tokyo. 1979), 2016-02, Vol.38 (2), p.209-216 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment
Autor: Nishida, Kosuke ; Morioka, Ichiro ; Nakamachi, Yuji ; Kobayashi, Yoko ; Imanishi, Takamitsu ; Kawano, Seiji ; Iwatani, Sota ; Koda, Tsubasa ; Deguchi, Masashi ; Tanimura, Kenji ; Yamashita, Daisuke ; Nibu, Ken-ichi ; Funakoshi, Toru ; Ohashi, Masanobu ; Inoue, Naoki ; Iijima, Kazumoto ; Yamada, Hideto
Assuntos: Antiviral Agents - therapeutic use ; Antiviral Agents - urine ; Cohort Studies ; Cytomegalovirus - genetics ; Cytomegalovirus Infections - diagnosis ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - urine ; Female ; Ganciclovir - analogs & derivatives ; Ganciclovir - therapeutic use ; Hospital-based study ; Humans ; Infant, Newborn - urine ; Japan ; Japanese cohort ; Male ; Neonatal Screening - methods ; Neurological impairment ; Neurology ; Newborn urine screening ; Polymerase Chain Reaction ; Treatment Outcome ; Valganciclovir
É parte de: Brain & development (Tokyo. 1979), 2016-02, Vol.38 (2), p.209-216
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Abstract Background Newborn screening for urinary cytomegalovirus (CMV) and early introduction of antiviral treatment are expected to improve neurological outcomes in symptomatic congenital CMV-infected infants. This cohort study prospectively evaluated neurological outcomes in symptomatic congenital CMV-infected infants following the introduction of hospital-based newborn urinary CMV screening and antiviral treatment. Subjects/methods Following institutional review board approval and written informed consent from their parents, newborns were prospectively screened from 2009 to 2014 for urinary CMV-DNA by PCR within 1 week after birth at Kobe University Hospital and affiliated hospitals. CMV-positive newborns were further examined at Kobe University Hospital, and those diagnosed as symptomatic were treated with valganciclovir for 6 weeks plus immunoglobulin. Clinical neurological outcomes were evaluated at age ⩾12 months and categorized by the presence and severity of neurologic sequelae. Results Urine samples of 6348 newborns were screened, with 32 (0.50%) positive for CMV. Of these, 16 were diagnosed with symptomatic infection and 12 received antiviral treatment. Four infants developed severe impairment (33%), three developed mild impairment (25%), and five developed normally (42%). Conclusions This is the first Japanese report of neurological assessments in infants with symptomatic congenital CMV infection who received early diagnosis and antiviral treatment. Urinary screening, resulting in early diagnosis and treatment, may yield better neurological outcomes in symptomatic congenital CMV-infected infants.
Editor: Netherlands: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment

Netherlands: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.